1 / 16

Global Alzheimer’s Disease Drugs Market

iGATE RESEARCH report titled “Global Alzheimer’s Disease Drugs Market & Pipeline Drugs Market Analysis to 2020” is a 150 page report with 74 Figures and 10 Tables. This report analyses the Alzheimer’s Disease Drugs Market, Alzheimer’s Disease Pipeline Drugs Market and Clinical Trials Analysis, Alzheimer’s Disease - Country Wise Drugs Market, Country Wise Alzheimer’s Disease Prevalence, Major Deals in Alzheimer’s Disease Drugs Market Landscape, Funding in Alzheimer’s Disease Drugs Research, Driving Factors and Challenges for Alzheimer’s Disease Drugs Market. <br><br>The Alzheimer’s Disease Drugs Market has been analyzed from 7 View Points:<br><br>1. Alzheimer’s Disease - Drugs Sales and Forecast <br>2. Alzheimer’s Disease - Pipeline Drugs Sales Forecast<br>3. Alzheimer’s Disease Drugs - Country Wise Market and Forecast<br>4. Alzheimer’s Disease - Country Wise Prevalence and Forecast<br>5. Alzheimer’s Disease - Pipeline Drugs Clinical Trials Analysis<br>6. Alzheimer’s Disease - Major Deals in Alzheimer’s Drugs Market<br>7. Alzheimer’s Disease - Funding in Alzheimer’s Disease Research<br><br><br>The Top 9 Alzheimer’s Disease Drugs covered in the report are as follows:<br><br>1. Exelon <br>2. Razadyne/Reminyl<br>3. Memary<br>4. Ebixa<br>5. Aricept<br>6. Rivastach<br>7. Namenda<br>8. Nootropil<br>9. Namzaric<br><br>The 7 Pipeline Alzheimer’s Disease Drugs covered in the report are as follows:<br><br>1. Solanezumab<br>2. ABT-126<br>3. idalopirdine<br>4. Gantenerumab<br>5. Crenezumab<br>6. Lu AE58054<br>7. BIIB037<br><br><br>The 9 Countries Alzheimer’s Disease Drugs Market covered in the report are as follows:<br><br>1. United States<br>2. France<br>3. Germany<br>4. Italy<br>5. Spain<br>6. United Kingdom<br>7. Japan<br>8. China<br>9. India<br><br><br>The Alzheimer’s Disease Drugs Major Deals covered in the report are as follows:<br><br>1. Strategic Alliance<br>2. Licensing Agreement<br>3. Collaboration Deals<br>4. Mergers and Acquisitions <br><br><br>Click here to view the complete report: http://www.igateresearch.com/ProductDetail.php?pd_name=Global Alzheimers Disease Drugs Market Analysis<br><br>Contact US<br><br>iGATE Research PVT LTD<br><br>Ravi Sinha<br>Sales Manager<br>Marketing and Sales Divison<br>Email: ravi.sinha@igateresearch.com<br>Contact: 91-858-684-0791, 91-706-527-9335 (INDIA) <br>Web: www.igateresearch.com

IGATERESEARCH
Download Presentation

Global Alzheimer’s Disease Drugs Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Table of Contents Executive Summary 2. Global Alzheimer’s Disease - Drugs Market and Prevalence Analysis 2.1 Global Alzheimer’s Disease - Drugs Market and Forecast (2010 - 2020) 2.2 Global Alzheimer’s Disease - Prevalence and Forecast (2010 - 2020) 3. Global Alzheimer’s Disease - Country Wise Market Share and Forecast (2013 - 2020)

  2. 4. Global Alzheimer’s Disease - Drugs Sales and Forecast To 2020 4.1 Exelon (Rivastigmine) Sales and Forecast 4.2 Razadyne/ReminylSales and Forecast 4.3 Memary(Memantine) Sales and Forecast 4.4 Ebixa(Memantine) Sales and Forecast 4.5 Aricept (Donepezil) Sales and Forecast 4.6 RivastachSales and Forecast 4.7 Namenda (Memantine) Sales and Forecast 4.8 Nootropil(Piracetam) Sales and Forecast 4.9 Namzaric(Memantine and Donepezil) Sales and Forecast

  3. 5. Global Alzheimer’s Disease - Pipeline Drugs Analysis and Sales Forecast 5.1 Solanezumab Drugs Analysis and Sales Forecast 5.1.1 About Solanezumab 5.1.2 Clinical Trials 5.1.3 Solanezumab Drugs Sales Forecast 5.2 ABT-126 Drugs Analysis and Sales Forecast 5.2.1 About ABT-126 5.2.2 Clinical Trials 5.2.3 ABT-126 Drugs Sales Forecast

  4. Continue (www.igateresearch.com) 5.3 Idalopirdine Drugs Analysis and Sales Forecast 5.3.1 About Idalopirdine 5.3.2 Clinical Trials 5.3.3 Idalopirdine Drugs Sales Forecast 5.4 Gantenerumab Drugs Analysis and Sales Forecast 5.4.1 About Gantenerumab 5.4.2 Clinical Trials 5.4.3 Gantenerumab Drugs Sales Forecast

  5. Continue (www.igateresearch.com) 5.5 Crenezumab Drugs Analysis and Sales Forecast 5.5.1 About Crenezumab 5.5.2 Clinical Trials 5.5.3 Crenezumab Drugs Sales Forecast 5.6 Lu AE58054 Drugs Analysis and Sales Forecast 5.6.1 About Lu AE58054 5.6.2 Clinical Trials 5.6.3 Lu AE58054 Drugs Sales Forecast 5.7 BIIB037 Drugs Analysis and Sales Forecast 5.7.1 About BIIB037 5.7.2 Clinical Trials 5.7.3 BIIB037 Drugs Sales Forecast

  6. 6. Alzheimer’s Disease Drugs Market & Prevalence - Country Wise Analysis 6.1 United States - Alzheimer’s Disease Drugs Market & Prevalence Analysis 6.1.1 United States - Alzheimer’s Disease Drugs Market & Forecast (2013 - 2020) 6.1.2 United States - Alzheimer’s Disease Prevalence & Forecast (2010 - 2020) 6.2 France - Alzheimer’s Disease Drugs Market and Prevalence Analysis 6.2.1 France - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2020) 6.2.2 France - Alzheimer’s Disease Prevalence and Forecast (2012 - 2020) 6.3 Germany - Alzheimer’s Disease Drugs Market and Prevalence Analysis 6.3.1 Germany - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2020) 6.3.2 Germany - Alzheimer’s Disease Prevalence and Forecast (2012 - 2020)

  7. Continue (www.igateresearch.com) 6.4 Italy - Alzheimer’s Disease Drugs Market and Prevalence Analysis 6.4.1 Italy - Alzheimer’s Disease Drugs Market and Forecast (2013 - 2020) 6.4.2 Italy - Alzheimer’s Disease Prevalence and Forecast (2012 - 2020) 6.5 Spain - Alzheimer’s Disease Drugs Market & Prevalence Analysis 6.5.1 Spain - Alzheimer’s Disease Drugs Market & Forecast (2013 - 2020) 6.5.2 Spain - Alzheimer’s Disease Prevalence & Forecast (2012 - 2020) 6.6 United Kingdom - Alzheimer’s Disease Drugs Market & Prevalence Analysis 6.6.1 United Kingdom - Alzheimer’s Disease Drugs Market & Forecast (2013 - 2020) 6.6.2 United Kingdom - Alzheimer’s Disease Prevalence & Forecast (2012 - 2020)

  8. Continue (www.igateresearch.com) 6.7 Japan - Alzheimer’s Disease Drugs Market & Prevalence Analysis 6.7.1 Japan - Alzheimer’s Disease Drugs Market & Forecast (2013 - 2020) 6.7.2 Japan - Alzheimer’s Disease Prevalence & Forecast (2012 - 2020) 6.8 China - Alzheimer’s Disease Drugs Market & Prevalence Analysis 6.8.1 China - Alzheimer’s Disease Drugs Market & Forecast (2013 - 2020) 6.8.2 China - Alzheimer’s Disease Prevalence & Forecast (2010 - 2020) 6.9 India - Alzheimer’s Disease Drugs Market & Prevalence Analysis 6.9.1 India - Alzheimer’s Disease Drugs Market & Forecast (2013 - 2020) 6.9.2 India - Alzheimer’s Disease Prevalence & Forecast (2010 - 2020)

  9. 7. Global Alzheimer’s Disease Drugs Market - Major Deals Analysis 7.1 Global Alzheimer’s Disease Drugs Market - Strategic Alliance 7.2 Global Alzheimer’s Disease Drugs Market - Licensing Agreement 7.3 Global Alzheimer’s Disease Drugs Market - Collaboration Deals 7.4 Global Alzheimer’s Disease Drugs Market - Mergers and Acquisitions 8. Global Alzheimer’s Disease Drugs Research - Funding Analysis 8.1 National Institute of Health (2011 - 2016) 8.2 Alzheimer's Association (2011 - 2014) 8.3 Cure Alzheimer’s Fund (2008 - 2014) 8.4 Alzheimer’s Drug Discovery Foundation (2008 - 2013) 8.5 BrightFocusFoundation (2010 - 2014)

  10. 9. Global Alzheimer’s Disease Drug Market - Driving Factors 9.1 Growing Aging Population 9.1.1 Global Ageing Indicators 9.1.2 Population Aged 60 or Over: World and Development Regions, 1950 - 2050 9.1.3 Worldwide - Distribution of Population Aged 60 Years or Over By Broad Age Group, 1950 – 2050 9.2 Unmet Medical Needs 9.3 Strong Pipeline Candidate Expected to Drive Alzheimer’s Disease Drugs Market 9.4 Future Drugs for Disease Modification in Alzheimer’s Disease

  11. 10. Global Alzheimer’s Disease Drug Market - Challenges 10.1 Lack of Validated Targets & Lack of Animal Models 10.2 Barriers in the Design and Implementation of Clinical Trials 10.3 Barriers in Academia & Regulatory Issues 10.4 Alzheimer’s Drug Failure: Insinuation for Future R&D in Neuroscience 10.5 Costly Alzheimer’s Drug Development Dissuade Drug Companies 10.6 Research Setbacks and Stepping Stones 10.7 Country Wise Barriers to Growth for Alzheimer’s Disease Drugs Market 10.7.1 Unite States 10.7.2 France 10.7.3 Germany 10.7.4 United Kingdom 10.7.5 Japan 10.7.6 China 10.7.7 India

  12. Source of Information iGATERESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

  13. Published By iGATE RESEARCH Phone: +91-858-684-0791 (India) +91-706-527-9335 (India) Email: info@igateresearch.com Internet:www.igateresearch.com

  14. Format • Report Title: Global Alzheimer’s Disease Drugs Market and Pipeline Drugs Market Analysis to 2020 • To Order the Report Visit: • http://www.igateresearch.com/ProductDetail.php?pd_name=Global%20Alzheimers%20Disease%20Drugs%20Market%20Analysis

  15. Order the Report • iGATE RESEARCH PVT. LTD. • Web: www.igateresearch.com • To order the Report: • E-Mail:  info@igateresearch.com • Contact No. : +91-858-684-0791, +91-706-527-9335 (INDIA) • For Report Related Query: • E-Mail:  info@igateresearch.com • Contact No. : +91-858-684-0791, +91-706-527-9335 (INDIA)

More Related